Dublin, Aug. 22, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026" report to their offering.
The Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016-2026 report provides a comprehensive analysis of the current market landscape of these therapies and an informed opinion on how the market is likely to evolve over the next decade. The anti-diabetic drugs market broadly comprises of insulin and non-insulin therapies.
Non-insulin therapies are further classified under various categories based on their respective mechanisms of action. Of the different types of non-insulin therapies, GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors have been the most popular in the last few years. As mentioned earlier, these therapeutic classes have captured the attention of a number of pharmaceutical companies and drug developers worldwide.
Several companies, including pharmaceutical giants, mid-sized players and start-ups, have come up with innovative technologies and novel formulations of these drug classes. Such advances have generated and sustained significant momentum in this segment of the industry.
Specifically, GLP-1 agonists, which have been researched for several years, have a rich pipeline of clinical and preclinical molecules. DPP4 inhibitors currently have a relatively larger market share; however, they are now giving way to other relatively newer and emerging classes such as SGLT2 inhibitors.
During the course of our study, we identified over 80 molecules belonging to these three drugs classes. More than 70% of the candidates are currently under clinical / preclinical development; the efforts are actively being led by several companies.
Focused primarily on these three classes of drugs, this report features:
- An overview of the market landscape highlighting important details on each molecule such as key players, current phase of product development, route of administration and dosage regime.
- Detailed profiles of drugs that have been recently approved / marketed or are in the late stages of development.
- A list of key opinion leaders (KOLs) who were involved in the discovery and development of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors.
- An analysis of recently published clinical trial data depicting the prevalent trends and technical developments that have taken place in the industry.
- A discussion on the potential side effects and warnings issued by regulatory authorities suggesting areas of improvement / guidance for future drug development.
- A list of upcoming non-insulin novel therapies that are currently in early stages of development and likely to become a part of the anti-diabetic drugs market in the near future.
The report also provides an estimate of the likely future size of the non-insulin therapies for diabetes. Our forecast model was built based on an understanding of the existing market trends and likely future opportunities for GLP-1 agonists, DPP4 inhibitors, SGLT2 inhibitors and other non-insulin anti-diabetic drug classes. We have provided informed estimates of the expected future sales of marketed and late stage product candidates under each category, highlighting their share in the overall market over the next ten years.
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzedfrom publicly available data. Unless otherwise specified, all financial figures are presented in USD.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Market Overview
5. GLP-1 Agonists
6. DPP4 Inhibitors / CD26 Antigen Antagonists
7. SGLT2 Inhibitors
8. Discontinued Molecules and Common Side Effects
9. Novel Non-Insulin Therapies for Diabetes
10. Market Forecast
11. Publication Analysis
12. KOL Analysis
13. Interview Transcripts
14. Conclusion
15. Appendix 1: Tabulated Data
16. Appendix 2: List of Companies and Organizations (Partial List)
- 3sBio
- Aalborg Hospital
- Aarhus University Hospital
- Abbott Laboratories
- ActivX Biosciences
- Addex Therapeutics
- Aegis Therapeutics
- AGDUC
- AIDS Clinical Trials Group
- Ajinomoto
- Alantos Pharmaceuticals
- Albert Einstein College of Medicine
- Alize Pharma
- Alkem Labs
- Alkermers
- Allegheny Health Network
- Allergan
- Almirall
- Alteogen
- ALZA Pharmaceuticals
- American Association of Clinical Endocrinologists
- American Diabetes Association
- American Heart Association
- Amgen
- Amunix
- Amylin Pharmaceuticals
- AntriaBio
- ArisGen
- Arisaph Pharmaceuticals
- Asan Medical Center
- Ascendis Pharma
- Bristol-Myers Squibb
- C4XD
- Cadila Healthcare Limited
- Cambridge Healthtech Institute
- Carl T. Hayden Medical Research Foundation
- Cedars-Sinai Medical Center
- Celerion
- Celgene
- CellMed
- Center for Human Drug Research
- Cornell CRS
- CoSynance Therapeutics
- CSL Behring
- CSPC Pharma
- CureDM
- CymaBay Therapeutics
- Daewoong Pharmaceutical
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Dance Biopharm
- Diabetes Foundation
- Diabeteszentrum Bad Lauterberg
- Diabetes-Zentrum Quakenbruck
- Diabetology
- Diamyd Medical
- Diartis Pharmaceuticals
- Glasgow Royal Infirmary
- Glenmark Pharmaceuticals
- Glide Technologies
- Grady Memorial Hospital
- Greensboro CRS
- Guy's and St Thomas' Hospitals
- GWT-TUD
- Hyundai Pharmaceutical
- Ildong Pharmaceutical
- Ilsan Hospital
- ImmuPharma
- Imperial College London
- Indiana University
- Institut de Recherches Cliniques de Montreal
- Institut für Pharmakologie und Präventive Medizin
- Institut National de la Santé Et de la Recherche Médicale
- Institute for Medical Research
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Kurume University
- Kyorin Pharmaceutical
- Kyoto University
- Kyowa Hakko Kirin Company
- Kyunghee University Medical Center
- Laval University
- Leicester General Hospital
- Leiden University Medical Center
- Lexicon
- LG Life Sciences
- Ligand Pharmaceuticals
- Lund University
- MonoSol Rx
- Mount Sinai Hospital, Canada
- Mountain Diabetes and Endocrine Center
- MultiMedica
- Nanjing Drum Tower Hospital
- National Cerebral and Cardiovascular Center
- National Health Research Institutes
- National Institues of Health
- National Institute for Health and Care Excellence
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute on Aging
- National Taiwan University Hospital
- Nemours Children's Clinic
- New Enterprise Associates
- New Leaf Venture Partners
- New York Obesity Nutrition Research Center
- Pharmaceutical Product Development
- PharmaIN
- Pharmsynthez
- PhaseBio Pharmaceuticals
- Phenomix
- Phoenix VA Healthcare System
- Phoundry Pharmaceuticals
- Pitié-Salpêtrière Hospital
- Palatin Technologies
- Pontificia Universidad Catolica de Chile
- Population Health Research Institute
- Post Graduate Institute of Medical Education and Research
- Poxel
- Prism Research
- Probiodrug
- Profil Institut für Stoffwechselforschung
- Sanofi
- Sanwa Kagaku Kenkyusho
- Sao Paulo General Hospital
- SatRx
- Scientisic Research Institute of Cardiology and Internal Diseases
- ScinoPharm
- Seattle Children's Hospital
- Second University of Naples
- Second Xiangya Hospital of Central South University
- Seoul National University Bundang Hospital
- Seoul St. Mary's Hospital
- Serometrix
- Services Hospital
- Servier
- Severance Hospital
- Shandong Provincial Hospital
- Shanghai Jiao Tong University School of Medicine
- Shanghai Mental Health Center
- Shanghai Sixth People's Hospital
- Sheba Medical Center
- Sirona Biochem
- Slotervaart Hospital
- Spitfire Pharma
- St Michael's Hospital
- St. Josef Hospital
- St. Joseph's Health Care, London
- Stanford University
- Stendhal
- Steno Diabetes Center
- Theratechnologies
- Third Military Medical University, China
- Thomas Jefferson University
- TIMI Study Group
- University Medical Center Hamburg-Eppendorf
- University Medical Center Ljubljana,Slovenia
- University Nijmegen Medical Center
- University of Aarhus
- University of Adelaide
- University of Alabama at Birmingham
- University of Alberta
- University of Amsterdam
- University of Birmingham
- University of Minnesota
- University of Munich
- University of Nebraska-Lincoln
- University of Nevada School of Medicine
- University of North Carolina, Chapel Hill
- University of Nottingham
- University of Oulu
- University of Padova Medical School
- University of Palermo
- University of Pennsylvania
- University of Pittsburgh
- University of São Paulo General Hospital
- University of Southern California
- University of Surrey
- University of Tartu
- University of Texas
- University of Texas Health Science Center
- University of Texas Medical Branch
- University of the Ryukyus
- University of Tokyo
- University of Toronto
- University of Washington
- University of Western Ontario
- Uppsala University
- UT Southwestern Medical Center
- VA Puget Sound Health Care System
- Vall d'Hebron Research Institute
- Vanderbilt University School of Medicine
- Velocity Pharmaceutical Development
- Venrock
- Viking Therapeutics
- Vitae Pharmaceuticals
- VIVUS
- vTv Therapeutics
- VU University Medical Center
- Wake Forest University / Wake Forest University Health Sciences
- Walter Reed Army Medical Center- Diabetes Institute
- Wan Fang Hospital
- Wanbang Biopharmaceuticals (subsidiary of Shanghai Pharmaceutical Group)
- Washington University CRS
- Washington University School of Medicine
- Woman's Hospital
- World Health Organization
- Wuhan General Hospital of Guangzhou Command
- Xenetic Biosciences
- Yale University
- Yeshiva University
- Yokohama City University School of Medicine
- Yuhan
- Zealand Pharma
- Zosano Pharma
- Zydus Cadila
- ZymoGenetics
For more information about this report visit http://www.researchandmarkets.com/research/qm5g3j/noninsulin
Related Topics: Immune Disorders Drugs, Endocrinology